Indeed, an analysis by Wang and colleagues determined that RET fusion-positive lung carcinomas had more poorly differentiated tumors compared to those with ALK or EGFR alterations, indicating that RET fusions define a unique molecular and clinicopathological subtype of NSCLC (58). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.